Investigators assessed the diagnostic performance of AST to Platelet Ratio Index and Fibrosis-4 scores compared with transient elastography evaluation of liver stiffness to detect significant fibrosis or cirrhosis.
Researchers suggest that novel biologicals should be explored as a treatment alternative to hepatitis vaccination for patients who are being treated with immunosuppressive drugs.
Adult heart transplants from hepatitis C virus-positive (HCV+) donors appear safe, with no increased risk for adverse effects on one-year survival.
Researchers found data that showed schistosomiasis does not escalate liver damage in patients who are infected with the hepatitis B virus.
From a nationwide Swedish registry, researchers found data that showed in patients with hepatitis B or C virus infection, the long-term hepatocellular carcinoma risk was lower in patients who were treated with lipophilic statins.
Investigators found data that showed patients with hepatitis C virus infection who had a sustained viral response to treatment with interferon had less incidence of extrahepatic manifestations.
Drug interactions between antiretroviral therapy (ART) and direct-acting antivirals (DAAs) pose a clinical challenge in patients with HIV/hepatitis C virus (HCV) coinfection.
In this prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and with lower risk for progression to advanced fibrosis.
Researchers found data that showed less than 10% of people diagnosed with chronic hepatitis C virus infection received treatment with DAAs.
Findings of the analysis also revealed that some evidence indicates that liraglutide improves liver fat, liver function, and HbA1c, and may aid in NASH resolution and weight reduction.
Several physicians explore the etiology of osteopenia and osteoporosis in patients with HIV and HCV who are undergoing antiretroviral therapy.
In Canada, researchers found data that showed there is a need for mental health and addiction care for patients with hepatitis C infection.
In China, researchers found data that showed DAA-based therapies are safe in treating chronic hepatitis C.
Patients with hepatitis C virus (HCV) and cirrhosis can develop high-risk gastroesophageal varices (GEV) after sustained virological response (SVR). Surveillance is especially recommended in those with GEV before antiviral treatment.
A multicomponent intervention can improve hepatitis C virus (HCV) screening, although there is considerable variation by practice.
Of the 6 vascular injury markers measured, soluble vascular cell adhesion molecule 1 showed the strongest correlation with disease parameters.
Dried blood spot specimens could be a reliable alternative testing specimen, which may increase hepatitis B and C diagnostic opportunities for rural, remote, and hard to reach regions.
Clinical trials evaluating seladelpar for the treatment of non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) have been halted after atypical histological findings were observed in a phase 2b study in NASH patients.
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for obeticholic acid (Intercept) for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).
Researchers found data that showed patients who have or who are injecting drugs would benefit from treatment for HCV with direct-acting antivirals.